Foetal exposure to oral retinoids products containing acitretin, alitretinoin and isotretinoin presents a high risk of congenital malformations.

Oral retinoids products are strictly contraindicated in women of childbearing potential, unless all conditions in products Pregnancy Prevention Programme are fulfilled.

Educational materials present on this website are an additional measure used to reduce the risk associated with using oral retinoids products for healthcare professionals and patients.*
Before initiating therapy please read the Summary of Product Characteristics (for healthcare professionals) or the Package Information Leaflet (for patients).

* The recommendation of the European Medicines Agency (EMA) in agreement with the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, implemented by the Marketing Authorization Holder PharmaSwiss Ceska Republika s.r.o.